CompletedPhase 1

Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)

36 participantsStarted 2008-01

Plain-language summary

A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers

Who can participate

Age range20 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical normal physical findings, including BP, pulse rate \>45 bpm, ECG and laboratory assessments * Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg. * Non-fertile females Exclusion Criteria: * History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator. * History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the Investigator.

What they're measuring

VAS, HPT

Timeframe: Visit 2-4

Trial details

NCT IDNCT00692146

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-05

View on ClinicalTrials.gov More Capsaicin Evoked Pain trials